Development, Piloting and Evaluation of an evidence-based informed consent form for total knee arthroplasty (EvAb-Pilot): A protocol for a mixed methods study

Alina Weise (Alina.Weise@uni-wh.de)  
Witten/Herdecke University  
https://orcid.org/0000-0003-4563-5782

Julia Lühnen  
Martin Luther University of Halle Wittenberg Faculty of Medicine: Martin-Luther-Universitat Halle-Wittenberg Medizinische Fakultat

Stefanie Bühn  
University of Witten/Herdecke: Universitat Witten/Herdecke

Felicia Steffen  
Martin-Luther-Universitat Halle-Wittenberg Juristische und Wirtschaftswissenschaftliche Fakultat

Sandro Zacher  
Martin-Luther-Universitat Halle-Wittenberg Medizinische Fakultat

Lauberger Julia  
Martin-Luther-Universitat Halle-Wittenberg Medizinische Fakultat

Deha Murat Ates  
Hospital Cologne-Merheim Clinic for Trauma and Orthopedic Surgery

Andreas Böhmer  
Hospital Cologne-Merheim Clinic for Anaesthesiology and Operative Intensive Medicine: Krankenhaus Köln-Merheim Klinik fur Anasthesiologie und operative Intensivmedizin

Henning Rosenau  
Martin-Luther-Universitat Halle Wittenberg Juristische und Wirtschaftswissenschaftliche Fakultat

Anke Steckelberg  
Martin-Luther-Universitat Halle-Wittenberg Medizinische Fakultat

Tim Mathes  
University of Witten/Herdecke: Universitat Witten/Herdecke

Study Protocol

Keywords: informed consent, informed consent form, risk communication, evidence-based health information, nocebo effect, anxiety, total knee arthroplasty (TKA)

DOI: https://doi.org/10.21203/rs.3.rs-132415/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License


Abstract

Background: Practitioners frequently use informed consent forms to support the physician-patient communication and the informed consent process. Informed consent for surgery often focuses on risk centered information due to high liability risks for treatment errors. This may affect patients’ anxiety of adverse events and the nocebo effect. This study focuses on the optimization of pre-surgical information on risks and complications, and at the same time reconcile these information with legal requirements.

Methods: The development, piloting and evaluation of evidence-based informed consent forms for total knee arthroplasty (TKA) and related anesthesia procedures will follow the UK MRC Framework for developing and evaluating complex interventions. Conducting different sub-studies, we will (I) qualitatively explore the information acquisition and decision making processes, (II) develop and pilot test evidence-based informed consent forms on the example of TKA and related anesthesia procedures, (III) conduct a monocentric interrupted time series (ITS) pilot study to evaluate the effects of evidence-based informed consent forms in comparison with standard consent forms and (IV) perform a process evaluation to identify barriers and facilitators to the implementation of the intervention and to analyze mechanisms of impact.

Discussion: The evidence-based and understandable presentation of risks in informed consent forms aims at avoiding distorted risk depiction and strengthening the patients’ competences to correctly assess the risks of undergoing surgery. This might reduce negative expectations and anxiety of adverse events, which in turn might reduce the nocebo effect. At the same time, the practitioners’ acceptance of evidence-based informed consent forms meeting legal requirements could be increased.

Trial Registration:

ClinicalTrials.gov, NCT04669483. Registered 15 December 2020, https://www.clinicaltrials.gov/ct2/show/NCT04669483?term=NCT04669483&draw=2&rank=1

German Clinical Trials Registry, DRKS00022571. Registered 15 December 2020, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022571

Introduction

Background and rationale

In most countries, every medical intervention requires informed consent (1–4). Appropriate informed consent procedures may include the presentation of comprehensible information about the necessity and kind of the intervention, mechanism of action, material risks and consequences or alternative treatments (3, 5). The principle of informed consent, is based on the human right for self-determination and the ethical principle of autonomy (2, 6). Informed consent is not only required by ethical aspects, but also incorporated in legal requirements. These legal requirements vary between countries (1–3). The Council of Europe’s Convention on Human Rights and Biomedicine (chapter II, article 5), for example, declares that ‘an intervention in the health field may only be carried out after the person concerned has given free and informed consent to it. This person shall beforehand be given appropriate information as to the purpose and nature of the intervention as well as on its consequences and risk.’ For example in Germany, the role of patients has been strengthened by the Patient Rights Act in 2013 (Patientenrechtegesetz), that is incorporated into the Civil Code (para. 630a-630 h BGB). Although, verbal consent is sufficient, practitioners in Germany frequently use informed consent forms to support the physician-patient-communication and to document written informed consent (5). In contrast, the U.S. American law requires written informed consent as a prerequisite for interfering with the patient’s physical integrity (1).

This study aims at investigating the effects of evidence-based informed consent forms for total knee arthroplasty (TKA) and relating anesthesia procedures. Usually, informed consent for surgery does not primarily aim at proving adequate information to support an informed decision, because the decision for or against the medical intervention is usually made before hospital admission, e.g. during first consultation in primary care. However, it is not ensured that relevant information for the decision is provided in these consultations. Due to high liability risks for treatment errors, informed consent for surgery and related consent forms often focus on risk-centered information (3, 4, 7). The way of presenting treatment risks can affect patients’ anxiety and the nocebo effect, which can be defined as ‘unpleasant or adverse outcomes triggered by the treatment context, beyond any inherent [...] effects of the treatment itself’ (8) (9–11). Previous research shows that supporting documents (e.g. informed consent forms) used in practice are heterogeneous (12, 13) and that they are often deficient regarding the communication of risks (13).

Objectives

The overall aim of this project is to investigate whether newly developed evidence-based informed consent forms for surgery and anesthesia (on the example of TKA) can reduce the deficits of the standardized consent forms regarding patients’ anxiety, nocebo effects and risk perception. For this purpose, we will develop evidence-based informed consent forms and compare them with standard consent forms as used in routine care in Germany.

Specifically, we will perform the following sub-studies:

I. Qualitatively explore the information acquisition process and the decision-making processes
II. Develop (including pilot testing) evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures (regional and general anesthesia)
III. Conduct an interrupted time series (ITS) pilot study to test the effects of evidence-based informed consent forms in comparison with standard consent forms
IV. Perform a formative process evaluation to identify barriers and facilitators to the implementation of the intervention and to analyze contextual factors and mechanisms of impact

**Logic Model**

The potential impact of information presented in informed consent forms on health outcomes depends on complex processes. Figure 1 depicts these complex processes and how informed consent forms may affect health outcomes.

*Figure 1 Logic Model*

Negative expectations are important elements of the complex processes which may produce nocebo effects (11). Negative expectations are caused by negative stimuli, which are the results of assimilating internal and external factors through complex cognitive-emotional-processes (14). In our study context, external factors are primarily the information from informed consent forms and pre-existing health literacy and other information. The source and content of information and the presentation of information may influence which subjective meaning is given to the information. Assimilating these external factors can evoke internal factors, in particular emotions like fear or even anxiety (14).

Via (neuro-)physiological pathways negative expectations, caused by the negative stimuli, may influence the likelihood of experiencing these expectations (e.g., headaches). This may in turn negatively affect the quality of life (15, 16).

In addition, anxiety (17) and dissatisfaction with the decision may have an immediate negative impact on quality of life.

**Methods**

The development, piloting and evaluation of evidence-based informed consent forms for TKA and related anesthesia procedures will follow the UK MRC Framework for developing and evaluating complex interventions (18). The UK MRC Framework describes four key elements of the development and evaluation process: 1) Development, 2) Feasibility/Piloting 3) Evaluation and 4) Implementation. This study will include the first two key elements: Sub-study I and II will be performed for developing the intervention; Sub-study III and IV will be performed for exploring feasibility and pilot testing the intervention (see Fig. 2).

*Figure 2 Sub-Studies in accordance with the UK MRC Framework*

This study protocol is reported according to the *Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)* (19), where applicable.

The study – including all sub-studies – is approved by the Ethics committee of the Witten/Herdecke University. We will receive written informed consent from all participants prior to inclusion.

**Development**

We will perform sub-study I and II to develop the intervention.

**Sub-study I: Exploration of the information acquisition process and the decision-making processes**

We will explore the information acquisition processes and the decision-making processes to better understand the context in which the informed consent form is embedded. The informed consent on TKA and anesthesia is the final step in the decision-making process. Our aim is to describe the whole process to understand when, how and by whom decisions are made and what information is decisive. We will derive information needs and preferences of patients, and identify barriers and facilitators for the adequate use of evidence based informed consent forms in practice.

We will perform semi-structured interviews with patients and physicians. Patients, ≥ 18 years, with decision making capacity, considering TKA or with previous TKA in the last six months will be included. Physicians (orthopedics and anesthetists) obtaining informed consent in the clinic for orthopedics, trauma surgery and sports traumatology of the Cologne-Merheim hospital as well as referring orthopedics and primary care physicians are eligible. Physicians in the clinic will be personally addressed, referring physicians will be invited by email and phone. If they agree to participate, they will also receive information flyer for patients. Patients will be recruited by study nurses or physicians during the office hours of the clinic or ambulant consultations. Written informed consent will be obtained. Due to the corona pandemic, we will conduct online or telephone interviews. The interviews will be audio recorded and transcribed. Qualitative content analyses will be performed in an iterative process until data saturation is achieved (20).

In addition, written information (leaflets, decision aids, and consent forms) on TKA provided by participating physicians or received by included patients, will be collected and rated with EQIP (21) regarding criteria of evidence-based health information. Descriptive analysis will be performed.

**Sub-study II: Development and pilot testing of evidence-based informed consent forms**

**Development of evidence-based informed consent forms**

To promote informed choices, evidence-based informed consent forms on TKA and related anesthesia procedures (regional and general anesthesia) will be developed, taking insights from sub-study I and II into account. (22–26).

The design of the evidence-based informed consent forms, will be guided by an existing guideline on how to present evidence-based health information (*guideline evidence-based health information* (27)) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo (28). Verbal presentations of risks lead to
overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.

To generate quantitative information for the informed consent forms, we will perform systematic reviews on the comparative effectiveness and harms of TKA and related anesthesia procedures. Relevant questions will be derived from former consent forms, reviews, guidelines, patient preferences and in cooperation with the participating practitioners. We will include systematic reviews, randomized controlled trials and prospective cohort studies. For rare adverse events and complications we will consider database based studies such as medical device registries or adverse event reporting systems, in addition. The quality of evidence will be rated according to GRADE (29). Eligibility-screening of references, data extraction and critical appraisal will be performed by two independent reviewers.

To resume the current state of research, we will review comparative studies on written material to promote informed consent identified in previous systematic reviews on this topic (30, 31).

We will derive relevant information on benefits and risks for the knowledge test, for usage in the main study (objective III). The development will be based on previous experiences with the measurement of informed choice (32, 33).

Due to the special legal requirements for informed consent, we will prove evidence-based consent forms for satisfying legal requirements. The lawyers of our team will perform a comprehensive evaluation of case law and literature (monographs, articles, commentaries, especially on the §§ 630d, 630e BGB) on the legal aspects regarding informed consent in Germany. During this process, the legal scope that may result from more recent jurisdiction on the physician’s obligation to provide information and the requirements for evidence-based informed consent forms will be examined and compared. At the same time, the legal framework for future patient-oriented education is defined in the concept of informed consent.

**Pilot testing**

The new consent forms will be tested on comprehensibility, readability, acceptance and emotional response. Think-aloud interviews are planned, followed by at least two focus group interviews with patients of the target group. The interviews will be audio recorded and transcribed. Qualitative content analyses will be performed (20). The consent forms will be revised and tested in an iterative process until data saturation is achieved.

The knowledge questions for Sub-Study III will also be pilot tested. We will optimize the items and select the most appropriate for the knowledge test.

In addition, a member from the Health Information Department of the independent Institute for Quality and Efficiency in Health Care (IQWiG), clinical experts and lawyers from the respective scientific medical societies (The German Society for Endoprosthetics and The German Society for Anaesthesiology and Intensive Care Medicine, DGÄ) and the study center will review the informed consent forms.

**Feasibility/piloting**

**Sub-Study III: Monocentric Interrupted Time Series (ITS) Pilot Study**

We will conduct a monocentric pilot study. This pilot study will be performed following a pragmatic trial approach to increase applicability to the German context of informed consent procedures (34). Our primary analysis is an ITS analysis approach. Using an ITS analysis, will allow us to compare the outcome trend (level and/or slope changes) before and after the introduction of the newly developed evidence-based informed consent forms (35).

**Methods: Participants, Interventions and Outcomes**

**Study setting**

The study will be conducted in an urban region (Cologne) at a level III hospital in Germany (Cologne-Merheim Hospital).

**Eligibility criteria**

Participants eligible for inclusion in the study:

- Are scheduled for an elective total knee arthroplasty surgery
- Are at least 18 years old
- Are able to understand and speak German
- Are mentally competent to give consent and answer questions

Patients with revision or posttraumatic arthrosis will be excluded.

**Interventions**

We include two groups of participants before (pre) and after (post) the introduction of the intervention. The group in the pre period (control group) will give informed consent based on standard consent forms from the Thieme-compliance publisher (https://shop.thieme-compliance.de/patientenaufklaerung/thieme/de/Aufk%C3%A4rungsformen%28%C3%B6gen/c/00000), which represents routine care in the study center. The group in the post period (intervention group) will give informed consent based on our newly developed evidence-based informed consent forms (see objective II). The change of the informed consent forms will be introduced at a pre-specified time-point. The informed consent procedures for surgery and for anesthesia will be performed together as far as feasible in the usual hospital workflow.
In addition, physicians performing informed consent in the post phase will be offered a training in evidence-based decision-making to adequately implement the evidence-based informed consent forms. The training will be based on the basic curriculum for evidence-based decision-making, developed by the German Network for Evidence-based Medicine. A curriculum-based, blended learning training program for physicians and medical students has already been developed and pilot tested (36). This training will be converted to an e-learning module adapted to address evidence-based decision-making on TKA.

Blinding

Standard consent forms and evidence-based informed consent forms are obviously different. Therefore, blinding of medical staff will be impossible. We will not explicitly inform participants about receiving a ‘different’ informed consent form but only about the nature of the study. The statistical analysis will be performed blinded.

Outcomes and measurement instruments

We plan to measure the following patient-relevant outcomes:

- **Primary Outcomes:**
  - Anxiety: subjective fear/anxiety of adverse events possibly caused by surgery or anesthesia
    - Measuring instrument: numeric rating scale 0–10 and surgical fear questionnaire (37)
    - Measure: mean
  - Nocebo-effect: patient reported adverse events (e.g. headache after anesthesia)
    - Measuring instrument: questionnaire (including closed and open questions)
    - Measure: proportion of patients with complications or adverse events (and cumulative number of adverse events)

- **Secondary Outcomes:**
  - Knowledge or risk perception: questions for knowledge about benefits and risks
    - Measuring instrument: objective knowledge questions (e.g. correct risk assessment) derived in the development phase. The development will be based on previous experiences with the measure of informed choice (32, 33).
    - Measure: Proportion of correctly answered questions
  - Satisfaction with the physician-patient-communication and informed consent form
    - Measuring instrument: numeric rating scale 0–10
    - Measure: mean
  - Quality of life (QoL)
    - Measuring instrument: numeric rating scale 0–10
    - Measure: mean
  - Pain and function
    - Measuring instrument: Oxford Knee Score (38)
    - Measure: mean

Sample size

To our knowledge, no comparative studies on different informed consent forms for TKA and related anesthesia procedures in the German context exist so far. Therefore, a sufficient data basis for statistical sample size calculation is not available. With this pilot study, we aim to create the data basis for sample size calculation and detect unforeseen problems for a definitive trial to prove effectiveness. We calculated the sample size for this pilot study using the probability to identify unforeseen problems (39) as anticipated to provide a robust basis for a valid sample size calculation in a definitive trial.

We plan to include at least 220 participations (110 pre, 110 post) in the study. Based on findings from previous studies (10), we anticipate a dropout rate of 10% so that 198 participants can be included in the analysis. Using this sample size, unforeseen problems with a 2%-probability of occurrence can be identified with a probability of 98%.

Recruitment

Based on the yearly caseload of patients with TKA in the study center, we anticipate a recruitment phase of 24 months (12 months pre, 12 months post). Recruitment is expected to start in February 2021 and finish in January 2023. Study participants will be recruited by study nurses or physicians during the office hours of the clinic for orthopedics, trauma surgery and sports traumatology of the Cologne-Merheim hospital. There will be no financial incentives for participation.

Participant Timeline

Table 1 depicts the participant timeline. The study includes a pre-interruption and post-interruption-phase. Participants in the pre-phase will receive informed consent based on standard consent forms (control) while participants in the post-phase will receive informed consent based on the newly developed evidence-
based consent forms (intervention). Irrespective of the phase, all participating patients will follow the same study flow: Study enrollment of each patient will take place approximately 4 weeks before surgery. They will receive informed consent procedures for TKA approximately 2–4 days before surgery. The informed consent procedure for anesthesia takes place approximately 4 weeks or 2–4 days before surgery, depending on the patients’ morbidity and the flexibility in scheduling. Outcomes will be measured at four specific time points for each patient: at the day of enrollment, 1 day before surgery, 3 days and 30 days after discharge from hospital.

| Table 1 | Participant timeline (SPIRIT figure) |
|---------|-------------------------------------|
| STUDY PERIOD (25 month) | |
| | Pre-Phase | Interruption | Post-Phase |
| | TIME-POINT | 4 weeks before surgery | 2–4 days before surgery | 1 day before surgery | surgery | 3 days after discharge | 30 days after discharge | 4 weeks before surgery | 2–4 day before surgery | 1 day before surgery |
| ENROLMENT | Eligibility screen | X | | | | | | | | |
| | Informed consent | | X | | | | | | |
| CONTROL | Standard consent form anesthesia | X* | X* | | | | | | |
| | Standard consent form TKA | | | X | | | | | |
| INTERVENTION | Evidence-based consent form anesthesia | | | | | | X* | X* | |
| | Evidence-based consent form TKA | | | | | | | | |
| | Surgery | X | | | | | | | |
| ASSESSMENTS | Patient characteristics | X | | | | | | | X |
| | Baseline anxiety | | X | | | | | | X |
| | Anxiety | | | X | | | | |
| | Health knowledge | | | X | | | | | X |
| | Satisfaction with physician-patient-communication | | | | X | | | | X |
| | Nocebo-effect | | | X | | | | | |
| | Quality of Life | | | | | X | | |
| | Pain and function | | | | | | X | |

*Informed consent for anesthesia takes place approximately 4 weeks or 2–4 days before surgery, depending on the patients’ morbidity and the flexibility in scheduling.

Methods: Data collection, management, and analysis

Data collection and management

We will collect the participants’ characteristics from the hospital information system (e.g. age) and using patient surveys (e.g. education). All outcomes will be collected with standardized patient surveys. All patient surveys will be performed by the same four interviewers based on an interviewer manual to ensure consistency.

Data will be collected using an electronic case report form (eCRF) and stored in an electronic data management system (REDCap) (40, 41). The eCRF and data management system will be piloted with dummy participants. We will perform a sample of double data entry to prove data quality. Only authorized study personal will have access to the data management system.

To ensure high retention, the participants’ expenditure of time for study participation will be kept as low as possible. Moreover, due to the nature of the intervention, there will be no physical strain for the participants caused by study participation.
**Statistical model**

We will report baseline characteristics of the study population and outcomes descriptively.

We will use an ITS analysis to determine level and slope changes after the implementation of the evidence-based informed consent forms. We will use segmented regression models for our analysis. The basic model is:

\[ Y_t = \beta_0 + \beta_1 T + \beta_2 X + \beta_3 TX \]

\(X_t\) is a Dummy which differentiates pre- and post-intervention periods. \(T\) identifies the course of time since the study has started. \(\beta_0\) is the base level. \(\beta_1\) is the course of the slope before the implementation of the intervention. \(\beta_2\) is the level change, which describes the immediate effect on \(Y\) after the implementation of intervention \(X\). \(\beta_3\) is the course of the slope after the implementation of the intervention. We will use negative-binomial regression models for all count data and multiple measure analysis of covariance for outcomes which can be analyzed as continuous variables.

We will create two models. One model will analyze the intervention as a complex package of measures on population level. The intervention effect will be analyzed on the hospital level. We will adjust the analysis for potential time-varying confounders (e.g., changes of the standard consent form by hospital information policies) and assess autocorrelation by examining the plot of residuals.

In a second model, we will analyze the intervention effect on an individual level. This means, the study is analyzed as historical cohort. In this model, the individual intervention components (informed consent forms, parallel performance of informed consent by orthopedic and aesthetic medical staff, participation on the training for evidence-based decision-making) are modeled as separate intervention components. We will perform this exploratory analysis to get insights into the isolated effect of evidence-based informed consent forms and interaction effects with other intervention components. We will adjust the models for baseline characteristics (e.g., age, sex, comorbidities, severity of disease) and a potential time trend (since the comparison group is a historical control).

In case >95% of data for an outcome are missing we will impute the missing data by multiple imputation using the Markov chain Monte Carlo method. In addition, to this primary analysis we will perform a best-case/worst-case analysis to assess the robustness of results depending on missing data (42).

To quantify the statistical uncertainty, the associated 95% confidence intervals will be provided for all effect estimates. As we conduct an explorative pilot study, we will not perform a test for statistically significant differences. We will prepare interrupted-time-series graphs to visualize the results (43).

All analyses will be performed using SAS software (44) and R (45).

**Methods: Monitoring**

Due to the nature of the intervention, there will be no data monitoring committee.

**Sub-Study IV: Process Evaluation**

Following the Medical Research Councils process evaluation framework for complex interventions (46), we will describe the intervention, its casual assumptions and the implementation process. We will analyze the contextual factors and the mechanisms of impact such as participant responses and mediators. The legal framework of informed consent will always be considered. Mixed methods will be applied to assess intervention fidelity, and the processes and mechanisms on different levels. The informed consent process will be documented on a standardized form (e.g., duration, orthopedist and anesthetist together, new informed consent form used yes/no, consent provided yes/no). The context will be explored using the Practice Adaptive Reserve Scale (47). Readiness to change on a healthcare professional level will be surveyed using the German Version of the Change Attitude Scale (48). Barriers and facilitators of implementation will be explored using qualitative methods. We will perform semi-structured interviews with patients and physicians. Participating orthopedists and anesthetists who regularly perform informed consent procedures and a random sample of patients in the intervention group (20% of participants) will be included. The selected patients will be contacted by telephone approximately one month after informed consent. At the end of the study, personal interviews with the physicians will be scheduled if possible. Otherwise, they will also be contacted by telephone. The interviews will be audio recorded and transcribed. Qualitative content analyses will be performed (20). A descriptive analysis will be performed on the quantitative data.

**Discussion And Practical Implications**

The evidence-based and understandable presentation of risks in informed consent forms aims at avoiding distorted risk depiction and strengthening the patients’ competence to correctly assess the risks of undergoing surgery. This might reduce negative expectations and anxiety of negative consequences, which in turn might reduce the nocebo effect. At the same time, the practitioners’ acceptance of evidence-based informed consent forms meeting legal requirements may be increased.

This study will be performed under routine conditions. Despite focusing on only one indication, we anticipate that the basic impact tendency may be generalized to other indications and settings. If this pilot study indicates positive effects of the newly developed evidence-based informed consent forms, it is planned to perform a definitive cluster-randomized trial for a wide range of different indications. Relations to publishers of informed consent forms already exist. Thus, if this pilot study indicates positive effects of evidence-based informed consent forms, this is a good starting situation to develop further evidence-based informed consent forms in cooperation. The use of informed consent forms is widespread. Therefore - premised a definitive study shows that the improvement of patient-relevant outcomes is possible - a large scale implementation could have an important positive impact on a population level.
List Of Abbreviations

BGB Bürgerliches Gesetzbuch (German Civil Code)
DGAI Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (German Society for Anaestesiology and Intensive Care Medicine)
DNebM Deutsches Netzwerk Evidenzbasierte Medizin (German Network for Evidence-based Medicine)
eCRF electronic Case Report Form
G-BA Gemeinsamer Bundesausschuss (German Federal Joint Committee)
ITS Interrupted Time Series
IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care)
QoL Quality of Life
REDCap Research Electronic Data Capture
SPIRIT Standard Protocol Items: Recommended for Interventional Trials
TKA Total Knee Arthroplasty
UK MRC United Kingdom Medical Research Council

Declarations

Administrative Information

Trial registration

ClinicalTrials.gov, NCT04669483. Registered 15 December 2020, https://www.clinicaltrials.gov/ct2/show/NCT04669483?term=NCT04669483&draw=2&rank=1

German Clinical Trials Registry, DRKS00022571. Registered 15 December 2020, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022571

Trial status

Recruitment is expected to start in February 2021 and finish in January 2023.

Protocol version

17.12.2020 EvAb-P-V1

Funding

The project, on which this publication is based, is funded by the Innovation Committee at the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) under the funding code: 01VSF19025. There are no other sources of financial, material or other support.

Roles and responsibilities

Trial sponsor: Institute for Research in Operative Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University; Ostmerheimer Str. 200, 51109 Cologne, Germany

Project leader: Dr. Tim Mathes, Institute for Research in Operative Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University; Ostmerheimer Str. 200, 51109 Cologne, Germany; e-mail: Tim.Mathes@uni-wh.de.

The study funder has no influence on study design; collection, management, analysis, and interpretation of data; writing of the report or the decision to submit the report for publication.

Authors' contributions

Concept-development for sub-study I: AS, JLü, SZ, JLa; concept-development for sub-study II: TM, AW, SB, AS, JLü, SZ, JLa, HR, FS, DA, AB; concept-development for sub-study III: TM, AW, SB, DA, AB; concept-development for sub-study IV: AS, JLü, SZ, JLa; Designing the statistical analysis plan: TM; project coordination: TM, AW, SB. All authors participated in writing the manuscript and approved the final version.

Acknowledgements
Ethics and dissemination

Research ethics approval

We received approval from the ethics committee of the Witten/Herdecke University.

Protocol amendments

Any changes or modifications to the study protocol can only be authorized by the project leader and will be made transparent as amendments in the study protocol. The ethics committee will be informed of any substantial changes to the study protocol. If necessary, the ethical approval will be updated.

Consent to participate

The request for willingness to participate and information about the study (III) will take place at consultation during office hours in the clinic for orthopedics, trauma surgery and sports traumatology of the Cologne-Merheim hospital. The research staff will inform the patient about rationale, background, objectives, potential risks, expected benefits, data usage and other relevant aspects of the study using a standardized written patient information and verbally. The patient will get sufficient time to resolve open questions and decide about participation. For participation in the study, the patient has to sign a written informed consent form, including agreement on data usage. The participant receives a copy of the written informed consent form. The participant can withdraw consent without any disadvantage.

Confidentiality

In this study, we will collect and process personal data and data on treatment and course of disease from participants. Data will be collected and electronically saved by research staff using patient identification numbers as pseudonyms. We will adhere to the “REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)”.

Declaration of interest/Competing interests

The authors declare that they have no competing interests.

Availability of Data and Materials

Anonymised data will be published at Open Science Framework https://osf.io/.

Dissemination policy

The results will be disseminated through open access publications in international peer-reviewed journals and by presentations at conferences for evidence-based medicine or healthcare research. The results will be published irrespective of whether they are positive or negative. Eligible authors are all individuals who meet the criteria for authorship according to the International Committee of Medical Journal Editors (49). In addition, the final study protocol including all amendments will be made available.

Consent for publication

Not applicable.

References

1. McCormack DJ, Gulati A, Mangwani J. Informed consent: a global perspective. Bone Joint J. 2018;100-b(6):687-92.
2. Aagaard L, Kristensen K. Off-label and unlicensed prescribing in Europe: implications for patients’ informed consent and liability. Int J Clin Pharm. 2018;40(3):509-12.
3. Hanson M, Pitt D. Informed consent for surgery: risk discussion and documentation. Can J Surg. 2017;60(1):69-70.
4. Skiba R, Sikotra N, Wilson A, Clay TD, Gabbay E. DOCTORS UNDERSTANDING OF CONSENT LAW. Intern Med J. 2020.
5. Parzeller M, Wenk M, Zedler B, Rothschild M. Aufklärung und Einwilligung bei ärztlichen Eingriffen. Dtsch Arztebl Int. 2007;104(9):576-.
6. James JT, Eakins DJ, Scully RR. Informed consent, shared-decision making and a reasonable patient's wishes based on a cross-sectional, national survey in the USA using a hypothetical scenario. BMJ Open. 2019;9(7):e028957.
7. Todd NV, Birch NC. Informed consent in spinal surgery. Bone Joint J. 2019;101-b(4):355-60.
8. Faasse K, Helfer SG, Barnes K, Colagiuri B, Geers AL. Experimental Assessment of Nocebo Effects and Nocebo Side Effects: Definitions, Study Design, and Implications for Psychiatry and Beyond. Front Psychiatry. 2019;10(396).
9. Colagiuri B, McGuinness K, Boakes RA, Butow PN. Warning about side effects can increase their occurrence: an experimental model using placebo treatment for sleep difficulty. Journal of psychopharmacology. 2012;26(12):1540-7.
10. Prediger B, Meyer E, Büchter R, Mathes T. Nocebo effects of a simplified package leaflet compared to unstandardised oral information and a standard package leaflet: a pilot randomised controlled trial. Trials. 2019;20(1):458.

11. Faasse K, Huynh A, Pearson S, Geers A, Helfer S, Colagiuri B. The Influence of Side Effect Information Framing on Nocebo Effects. Ann Behav Med. 2018;53.

12. Bhattacharyya T, Yeon H, Harris MB. The medical-legal aspects of informed consent in orthopaedic surgery. J Bone Joint Surg Am. 2005;87(11):2395-400.

13. Lühnen J, Mühlhauser I, Steckelberg A. Qualität von Aufklärungsbögen. Dtsch Arztebl International. 2018;115(22):377-83.

14. Schröder HG, R. Nocebo-Effekte. Plädoyer für eine wohlgeformte Kommunikation 2018 [Available from: https://www.k-i-e.com/nocebo-effekt/ Access Date 12-09-2020].

15. Hansen E, Zech N, Meissner K. Placebo und Nocebo: Wie einsetzen bzw. vermeiden? Der Internist. 2017;58.

16. Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334-55.

17. Peters ML, Sommer M, de Rijke JM, Kessels F, Heineman E, Patijn J, et al. Somatic and psychologic predictors of long-term unfavorable outcome after surgical intervention. Ann Surg. 2007;245(3):487-94.

18. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Int J Nurs Stud. 2013;50(5):587-92.

19. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-7.

20. Mayring P, Fenzl T. Qualitative Inhaltsanalyse. In: Baur N, Blasius J, editors. Handbuch Methoden der empirischen Sozialforschung. Wiesbaden: Springer Fachmedien Wiesbaden; 2014. p. 543-56.

21. Charvet-Berard AI, Chopard P, Pernevez TV. Measuring quality of patient information documents with an expanded EQIP scale. Patient Educ Couns. 2008;70(3):407-11.

22. Webster RK, Rubin GJ. Influencing Side-Effects to Medicinal Treatments: A Systematic Review of Brief Psychological Interventions. Front Psychiatry. 2019;9(775).

23. Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, et al. Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus. Psychother Psychosom. 2018;87(4):204-10.

24. Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13(6):608-18.

25. Trevena LJ, Battratt A, Butow P, Caldwell P. A systematic review on communicating with patients about evidence. J Eval Clin Pract. 2006;12(1):13-23.

26. O’Connor AM, Pennie RA, Dales RE. Framing effects on expectations, decisions, and side effects experienced: The case of influenza immunization. J Clin Epidemiol. 1996;49(11):1271-6.

27. Lühnen J AM, Mühlhauser I, Steckelberg A. Leitlinie evidenzbasierte Gesundheitsinformation Hamburg. 2017 [Available from: http://www.leitlinie-gesundheitsinformation.de/ Access Date: 12-09-2020].

28. Büchter RB, Fechtelpeter D, Knelangen M, Ehrlich M, Waltering A. Words or numbers? Communicating risk of adverse effects in written consumer health information: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2014;14(1):76.

29. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence proles and summary of ndings tables. J Clin Epidemiol. 2011;64(4):383-94.

30. Kinnersley P, Phillips K, Savage K, Kelly MJ, Farrell E, Morgan B, et al. Interventions to promote informed consent for patients undergoing surgical and other invasive healthcare procedures. Cochrane Database Syst Rev. 2013(7):Cd009445.

31. Glaser J, Nouri S, Fernandez A, Sudore RL, Schillinger D, Klein-Fedyshin M, et al. Interventions to Improve Patient Comprehension in Informed Consent for Medical and Surgical Procedures: An Updated Systematic Review. Med Decis Making. 2020;40(2):119-43.

32. Berger-Hoger B, Liethmann K, Muhlhauser I, Haastert B, Steckelberg A. Nurse-led coaching of shared decision-making for women with ductal carcinoma in situ in breast care centers: A cluster randomized controlled trial. Int J Nurs Stud. 2019;93:141-52.

33. Schröder HG, R. Nocebo-Effekte. Plädoyer für eine wohlgeformte Kommunikation 2018 [Available from: https://www.k-i-e.com/nocebo-effekt/ Access Date 12-09-2020].

34. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348-55.
40. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

41. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.

42. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.

43. Turner SL, Karahalios A, Forbes AB, Taijaard M, Grimshaw JM, Korevaar E, et al. Creating effective interrupted time series graphs: Review and recommendations. Res Synth Methods. 2020.

44. SAS Institute. The SAS system for Windows. SAS Inst., Cary, NC, USA; 2013.

45. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

46. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. Med J BMJ. 2015;350:h1258.

47. Miller WL, Crabtree BF, Nutting PA, Stange KC, Jaen CR. Primary care practice development: a relationship-centered approach. Ann Fam Med. 2010;8 Suppl 1:S68-79; s92.

48. Hower KI, Pfaff H, Kowalski C, Wensing M, Ansmann L. Measuring change attitudes in health care organizations. J Health Organ Manag. 2019;33(3):266-85.

49. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals 2019 [Available from: http://www.icmje.org/ Access Date 09-12-2020].